Skip to content
Review

Tumor endothelial cells as vascular immune gatekeepers: reprogramming the vascular-immune interface for cancer immunotherapy.

Oct 2026 · Cancer Letters · Vol 661, pp. 218908 · 0 citations · 229 references
Medicine

TL;DR

Overall, this review establishes endothelial reprogramming as a central strategy for overcoming vascular immune gatekeeping and provides a mechanistic framework for biomarker-guided vascular-immune combination therapies in solid tumors.

Abstract

Despite durable clinical responses to immunotherapy in a subset of patients, most solid tumors remain refractory owing to an immune-excluded phenotype characterized by limited trafficking, infiltration, and function of effector immune cells within the tumor microenvironment (TME). Tumor endothelial cells (TECs) function as vascular immune gatekeepers that orchestrate this process. Driven by persistent pro-angiogenic signaling and metabolic stress, TECs establish a multilayered immune barrier through structurally abnormal, poorly perfused vasculature, endothelial anergy, and active immunosuppressive programs. TECs directly suppress effector T-cell and natural killer (NK)-cell function through checkpoint-like ligands, death-ligand pathways, and immunometabolic mechanisms involving adenosine production and tryptophan catabolism. Simultaneously, they recruit, retain, and reprogram immunosuppressive leukocytes, thereby reinforcing immune exclusion and therapeutic resistance. Here, we propose a TEC-centric vascular immune gatekeeping framework and review strategies to reprogram tumor vessels from immune barriers into conduits for effective immune-cell trafficking and activation. We discuss endothelial-directed monotherapies that transiently normalize or reset TEC states, together with combination strategies integrating vascular modulation with immune checkpoint blockade, adoptive and innate immune-cell therapies, cancer vaccines, oncolytic viruses, STING agonists, and multifunctional antibodies. We also highlight key translational considerations, including biomarker-guided patient stratification, pharmacodynamic monitoring using mechanism-based endpoints, and optimization of treatment dose and scheduling within the vascular normalization window. Overall, this review establishes endothelial reprogramming as a central strategy for overcoming vascular immune gatekeeping and provides a mechanistic framework for biomarker-guided vascular-immune combination therapies in solid tumors.

View source

Similar papers

Review Open access Oct 2026

Innate immune cells in tumor immunity: dual roles, mechanistic insights, and therapeutic opportunities

The tumor microenvironment (TME) is a complex ecosystem that dynamically regulates tumor progression and therapeutic responses. Within this environment, innate immune cells play prominent dual roles, acting as both critical mediators of anti-tumor surveillance and facilitators of tumor immune escape. This review compre...

Song-Hang Xing, Jia-Yu Zhang, Shuang Wang et al. · 0 citations
Nov 2026

Endothelial senescence orchestrates the tumor immune microenvironment and immunotherapy response in non-small cell lung cancer.

The response of non-small cell lung cancer to immunotherapy is highly variable and shaped by a heterogeneous tumor microenvironment, yet the stromal drivers remain unclear. We identify senescent endothelial cells (ECs) as key regulators of immunotherapy efficacy. Multi-omics analyses across cancers reveal that ECs repr...

Xing-Peng Qiu, Hong-Quan Qin, Shi-Yi Deng et al. · 0 citations
Review Open access Oct 2026

Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy

Immune‐cell dynamics within the tumor microenvironment (TME) determine whether immune cells can reach, recognize, and sustain antitumor function against malignant cells under suppressive pressure. These dynamics are shaped by hypoxia, nutrient stress, cytokine and chemokine signaling, stromal architecture, vascular acc...

Pin Guo, Yi-Zhao Xie, R. Song et al. · 0 citations
Review Open access Oct 2026

CD8⁺ T Cell infiltration and spatial organization in cancer: mechanisms, barriers, and therapeutic strategies

The infiltration of tumors by CD8⁺ T lymphocytes is a critical determinant of antitumor immunity and response to immunotherapy. However, the presence of tumor-specific CD8⁺ T cells does not necessarily translate into effective tumor control, as multiple biological barriers can prevent their recruitment, spatial distrib...

Lylou Milian, Mannon Geindreau, Cassandre Pignol et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.